Limited Use — Reason for Use code 481, 657 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 481, 657 required
Write on scriptLU code 481, 657 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 481, 657
Reason for Use code 481
For the management of patients receiving palliative care*.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
Reason for Use code 657
For the treatment of patients receiving care at home* who have failed or are unable to tolerate oral alternatives, and who require an injectable option to manage their condition.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
*e.g., home care recipients, long-term care home residents.
No interchangeable product listed in the Ontario extract
Furosemide Injection USP · DIN 00527033
Manufacturer: Sandoz Canada Inc.; listing date 2017-02-28
Health Canada: Marketed since 2005-10-25 · brand FUROSEMIDE INJ USP · ATC C03CA01 FUROSEMIDE · form Liquid · route Intravenous, Intramuscular · ingredients FUROSEMIDE 10 MG/ML · company Sandoz canada incorporated · schedule Prescription
Furosemide Injection USP: Formulary list price $0.6055/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6055 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4431 · Verify on the e-Formulary ↗ (DIN 00527033)
Source record
DIN 00527033: Furosemide Injection USP
Raw flags: sec12=Y, sec3=Y
Item: 402800047; group id 558; item number 1496; lccId 00272; manufacturer id SDZ
Source form: Inj Sol (Preservative Free); strength: 10mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6055; ministry $0.6055
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00527033
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4431Interchangeable products
Furosemide Injection USP · DIN 02527502 · $0.6055
Shortage status: resolved shortage (ended 2021-03-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00527033
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Lasix · DIN 02224720 · 10mg/mL · oral liquid
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Lasix · DIN 02224720
Manufacturer: Sanofi Aventis Pharma; listing date 1999-01-07
Health Canada: Marketed since 2008-03-20 · brand LASIX ORAL SOLUTION · ATC C03CA01 FUROSEMIDE · form Solution · route Oral · ingredients FUROSEMIDE 10 MG/ML · company Sanofi-aventis canada inc · schedule Prescription
Lasix: Formulary list price $0.3610/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3610 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37372 · Verify on the e-Formulary ↗ (DIN 02224720)
Source record
DIN 02224720: Lasix
Raw flags: sec3=Y
Item: 402800030; group id 559; item number 1497; lccId None; manufacturer id SAV
Source form: O/L; strength: 10mg/mL
Recorded listing: General benefit
Source prices (unrounded): $0.3610; ministry $0.3610
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02224720
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37372
Shortage status: resolved shortage (ended 2025-12-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02224720
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Furosemide · DIN 00396788 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Furosemide · DIN 00396788
Manufacturer: Apotex Inc.; listing date 1996-10-01
Health Canada: Marketed since 1977-12-31 · brand APO-FUROSEMIDE · ATC C03CA01 FUROSEMIDE · form Tablet · route Oral · ingredients FUROSEMIDE 20 MG · company Apotex inc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2798 · Verify on the e-Formulary ↗ (DIN 00396788)
Source record
DIN 00396788: Apo-Furosemide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 402800019; group id 559; item number 1498; lccId None; manufacturer id APX
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0219; ministry $0.0218
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00396788
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2798Interchangeable products
Furosemide · DIN 02351420 · $0.0218
Lasix · DIN 02224690 · not recorded
Mint-Furosemide · DIN 02466759 · $0.0218
Teva-Furosemide · DIN 00337730 · $0.0218
Shortage status: resolved shortage (ended 2024-04-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00396788
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Furosemide · DIN 02466759 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Furosemide · DIN 02466759
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2018-11-29
Health Canada: Marketed since 2018-07-30 · brand MINT-FUROSEMIDE · ATC C03CA01 FUROSEMIDE · form Tablet · route Oral · ingredients FUROSEMIDE 20 MG · company Mint pharmaceuticals inc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95511 · Verify on the e-Formulary ↗ (DIN 02466759)
Source record
DIN 02466759: Mint-Furosemide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 402800019; group id 559; item number 1498; lccId None; manufacturer id MIN
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0219; ministry $0.0218
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02466759
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95511Interchangeable products
Apo-Furosemide · DIN 00396788 · $0.0218
Furosemide · DIN 02351420 · $0.0218
Lasix · DIN 02224690 · not recorded
Teva-Furosemide · DIN 00337730 · $0.0218
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02466759
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Furosemide · DIN 00337730 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Furosemide · DIN 00337730
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Health Canada: Marketed since 2012-07-11 · brand TEVA-FUROSEMIDE · ATC C03CA01 FUROSEMIDE · form Tablet · route Oral · ingredients FUROSEMIDE 20 MG · company Teva canada limited · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2333 · Verify on the e-Formulary ↗ (DIN 00337730)
Source record
DIN 00337730: Teva-Furosemide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 402800019; group id 559; item number 1498; lccId None; manufacturer id TEV
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0219; ministry $0.0218
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00337730
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2333Interchangeable products
Apo-Furosemide · DIN 00396788 · $0.0218
Furosemide · DIN 02351420 · $0.0218
Lasix · DIN 02224690 · not recorded
Mint-Furosemide · DIN 02466759 · $0.0218
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00337730
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Furosemide · DIN 00362166 · 40mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Furosemide · DIN 00362166
Manufacturer: Apotex Inc.; listing date 1996-10-01
Health Canada: Marketed since 1976-12-31 · brand APO-FUROSEMIDE · ATC C03CA01 FUROSEMIDE · form Tablet · route Oral · ingredients FUROSEMIDE 40 MG · company Apotex inc · schedule Prescription
Apo-Furosemide: Formulary list price $0.0327/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0327 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2472 · Verify on the e-Formulary ↗ (DIN 00362166)
Source record
DIN 00362166: Apo-Furosemide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 402800009; group id 559; item number 1499; lccId None; manufacturer id APX
Source form: Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0327; ministry $0.0327
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00362166
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2472Interchangeable products
Furosemide · DIN 02351439 · $0.0327
Lasix · DIN 02224704 · not recorded
Mint-Furosemide · DIN 02466767 · $0.0327
Teva-Furosemide · DIN 00337749 · $0.0327
Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00362166
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Furosemide · DIN 02466767 · 40mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Furosemide · DIN 02466767
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2018-11-29
Health Canada: Marketed since 2018-07-30 · brand MINT-FUROSEMIDE · ATC C03CA01 FUROSEMIDE · form Tablet · route Oral · ingredients FUROSEMIDE 40 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Furosemide: Formulary list price $0.0327/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0327 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95512 · Verify on the e-Formulary ↗ (DIN 02466767)
Source record
DIN 02466767: Mint-Furosemide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 402800009; group id 559; item number 1499; lccId None; manufacturer id MIN
Source form: Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0327; ministry $0.0327
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02466767
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95512Interchangeable products
Apo-Furosemide · DIN 00362166 · $0.0327
Furosemide · DIN 02351439 · $0.0327
Lasix · DIN 02224704 · not recorded
Teva-Furosemide · DIN 00337749 · $0.0327
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02466767
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Furosemide · DIN 00337749 · 40mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Furosemide · DIN 00337749
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Health Canada: Marketed since 2012-07-11 · brand TEVA-FUROSEMIDE · ATC C03CA01 FUROSEMIDE · form Tablet · route Oral · ingredients FUROSEMIDE 40 MG · company Teva canada limited · schedule Prescription
Teva-Furosemide: Formulary list price $0.0327/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0327 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2447 · Verify on the e-Formulary ↗ (DIN 00337749)
Source record
DIN 00337749: Teva-Furosemide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 402800009; group id 559; item number 1499; lccId None; manufacturer id TEV
Source form: Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0327; ministry $0.0327
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00337749
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2447Interchangeable products
Apo-Furosemide · DIN 00362166 · $0.0327
Furosemide · DIN 02351439 · $0.0327
Lasix · DIN 02224704 · not recorded
Mint-Furosemide · DIN 02466767 · $0.0327
Shortage status: resolved shortage (ended 2026-05-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00337749
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Lasix Special · DIN 02224755 · 500mg · tablet
Limited Use — Reason for Use code 33 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 33 required
Write on scriptLU code 33 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 33
Reason for Use code 33
For patients with severely impaired renal function refractory to conventional dosages of the drug.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Lasix Special · DIN 02224755
Manufacturer: Sanofi Aventis Pharma; listing date 1999-01-07
Health Canada: Marketed since 2008-05-07 · brand LASIX SPECIAL · ATC C03CA01 FUROSEMIDE · form Tablet · route Oral · ingredients FUROSEMIDE 500 MG · company Sanofi-aventis canada inc · schedule Prescription
Lasix Special: Formulary list price $3.5700/unit (unit not stated in source; not the patient's cost)
Ministry pays: $3.5700 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37375 · Verify on the e-Formulary ↗ (DIN 02224755)
Source record
DIN 02224755: Lasix Special
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 402800043; group id 560; item number 1500; lccId 00078; manufacturer id SAV
Source form: Tab; strength: 500mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $3.5700; ministry $3.5700
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02224755
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37375
Shortage status: resolved shortage (ended 2026-04-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02224755
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Limited Use — Reason for Use code 481, 657 requiredDormant since 2026-08-03 · checked 2026-09-02 · What does dormant mean?
StatusLimited Use — Reason for Use code 481, 657 required
Write on scriptLU code 481, 657 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 481, 657
Reason for Use code 481
For the management of patients receiving palliative care*.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
Reason for Use code 657
For the treatment of patients receiving care at home* who have failed or are unable to tolerate oral alternatives, and who require an injectable option to manage their condition.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
*e.g., home care recipients, long-term care home residents.
No interchangeable product listed in the Ontario extract
Furosemide Injection USP · DIN 02527502
Manufacturer: Jamp Pharma Corporation; listing date 2024-03-28
Health Canada: Dormant since 2026-08-03 · brand FUROSEMIDE INJECTION USP · ATC C03CA01 FUROSEMIDE · form Solution · route Intravenous, Intramuscular · ingredients FUROSEMIDE 10 MG/ML · company Jamp pharma corporation · schedule Prescription
Furosemide Injection USP: Formulary list price $0.6055/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6055 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101656 · Verify on the e-Formulary ↗ (DIN 02527502)
Source record
DIN 02527502: Furosemide Injection USP
Raw flags: sec12=Y, sec3=Y
Item: 402800047; group id 558; item number 1496; lccId 00272; manufacturer id JPC
Source form: Inj Sol (Preservative Free); strength: 10mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6055; ministry $0.6055
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02527502
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101656Interchangeable products
Furosemide Injection USP · DIN 00527033 · $0.6055
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02527502
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-08-03 — choose a marketed DIN from the same-category list.
Furosemide · DIN 02351420 · 20mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2024-06-05 — choose a marketed DIN from the same-category list.Discontinued 2024-06-05 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-06-05 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-06-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Furosemide · DIN 02351420
Manufacturer: Sanis Health Inc.; listing date 2020-10-30
Health Canada: Cancelled post market since 2024-06-05 · brand FUROSEMIDE · ATC C03CA01 FUROSEMIDE · form Tablet · route Oral · ingredients FUROSEMIDE 20 MG · company Sanis health inc · schedule Prescription
Furosemide: Formulary list price $0.0218/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0218 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83669 · Verify on the e-Formulary ↗ (DIN 02351420)
Source record
DIN 02351420: Furosemide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 402800019; group id 559; item number 1498; lccId None; manufacturer id SAI
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0218; ministry $0.0218
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02351420
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83669Interchangeable products
Apo-Furosemide · DIN 00396788 · $0.0218
Lasix · DIN 02224690 · not recorded
Mint-Furosemide · DIN 02466759 · $0.0218
Teva-Furosemide · DIN 00337730 · $0.0218
Shortage status: anticipated shortage (last updated 2026-03-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02351420
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-06-05 — choose a marketed DIN from the same-category list.
Furosemide · DIN 02351439 · 40mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2024-12-03 — choose a marketed DIN from the same-category list.Discontinued 2024-12-03 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-12-03 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-12-03 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Furosemide · DIN 02351439
Manufacturer: Sanis Health Inc.; listing date 2020-10-30
Health Canada: Cancelled post market since 2024-12-03 · brand FUROSEMIDE · ATC C03CA01 FUROSEMIDE · form Tablet · route Oral · ingredients FUROSEMIDE 40 MG · company Sanis health inc · schedule Prescription
Furosemide: Formulary list price $0.0327/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0327 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83670 · Verify on the e-Formulary ↗ (DIN 02351439)
Source record
DIN 02351439: Furosemide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 402800009; group id 559; item number 1499; lccId None; manufacturer id SAI
Source form: Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0327; ministry $0.0327
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02351439
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83670Interchangeable products
Apo-Furosemide · DIN 00362166 · $0.0327
Lasix · DIN 02224704 · not recorded
Mint-Furosemide · DIN 02466767 · $0.0327
Teva-Furosemide · DIN 00337749 · $0.0327
Shortage status: active shortage (reported 2025-12-08, last updated 2025-12-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02351439
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-12-03 — choose a marketed DIN from the same-category list.
Lasix · DIN 02224690 · 20mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2014-06-09 — choose a marketed DIN from the same-category list.Discontinued 2014-06-09 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2014-06-09 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2014-06-09 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lasix · DIN 02224690
Manufacturer: Sanofi Aventis Pharma; listing date 1999-01-06
Health Canada: Cancelled post market since 2014-06-09 · brand LASIX · ATC C03CA01 FUROSEMIDE · form Tablet · route Oral · ingredients FUROSEMIDE 20 MG · company Sanofi-aventis canada inc · schedule Prescription
Lasix: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37369 · Verify on the e-Formulary ↗ (DIN 02224690)
Source record
DIN 02224690: Lasix
Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y
Item: 402800019; group id 559; item number 1498; lccId None; manufacturer id SAV
Source form: Tab; strength: 20mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02224690
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37369Interchangeable products
Apo-Furosemide · DIN 00396788 · $0.0218
Furosemide · DIN 02351420 · $0.0218
Mint-Furosemide · DIN 02466759 · $0.0218
Teva-Furosemide · DIN 00337730 · $0.0218
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02224690
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2014-06-09 — choose a marketed DIN from the same-category list.
Lasix · DIN 02224704 · 40mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2014-06-09 — choose a marketed DIN from the same-category list.Discontinued 2014-06-09 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2014-06-09 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2014-06-09 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lasix · DIN 02224704
Manufacturer: Sanofi Aventis Pharma; listing date 1999-01-07
Health Canada: Cancelled post market since 2014-06-09 · brand LASIX · ATC C03CA01 FUROSEMIDE · form Tablet · route Oral · ingredients FUROSEMIDE 40 MG · company Sanofi-aventis canada inc · schedule Prescription
Lasix: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37370 · Verify on the e-Formulary ↗ (DIN 02224704)
Source record
DIN 02224704: Lasix
Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y
Item: 402800009; group id 559; item number 1499; lccId None; manufacturer id SAV
Source form: Tab; strength: 40mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02224704
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37370Interchangeable products
Apo-Furosemide · DIN 00362166 · $0.0327
Furosemide · DIN 02351439 · $0.0327
Mint-Furosemide · DIN 02466767 · $0.0327
Teva-Furosemide · DIN 00337749 · $0.0327
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02224704
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2014-06-09 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (40:28 Diuretics) and how they are covered
Matched class: 40:28 Diuretics
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: AMILORIDE HCL, METOLAZONE, SPIRONOLACTONE
Some products covered without a code (check the product listing): AMILORIDE HCL & HYDROCHLOROTHIAZIDE, CHLORTHALIDONE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE & SPIRONOLACTONE, HYDROCHLOROTHIAZIDE & TRIAMTERENE, INDAPAMIDE
40:28 Diuretics
INDICATIONS AND CLINICAL USE
TEVA-FUROSEMIDE (furosemide) is indicated for:
The treatment of edema associated with congestive heart failure, cirrhosis of the liver and
renal disease including, nephrotic syndrome, as well as other edematous states amenable to
diuretic therapy.
Can also be used alone in the control of mild to moderate hypertension, or in combination
with other antihypertensive agents in more severe cases.
Hypertensive patients who cannot be adequately controlled with thiazides will probably also not
be adequately controllable with furosemide alone.
3
Pediatrics
When administered to children, TEVA-FUROSEMIDE therapy should be instituted in the
hospital, in carefully selected patients, under close observation with frequent monitoring of
serum electrolytes (see DOSAGE AND ADMINISTRATION section).
The available pediatric data does not allow for a recommendation of a specific age range in this
population.
Geriatrics (> 61 years of age)
Use in the geriatric population is associated with differences in safety (see WARNINGS AND
PRECAUTIONS).
https://pdf.hres.ca/dpd_pm/00055547.PDF
PM date: March 24, 2020
Source product: TEVA-FUROSEMIDE; DIN 00337730; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Teva-Furosemide · DIN 00337730
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00337730
Furosemide · DIN 02351439
Shortage status: active shortage (reported 2025-12-08, last updated 2025-12-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02351439
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)
Other review policies
For Lasix: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.